Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide. The gene discussed is HSP90AB1; the disease is inflammatory breast carcinoma.